Literature DB >> 25502310

Treatment outcomes of the patients with early glottic cancer treated with initial radiotherapy and salvaged by conservative surgery.

Aya Harada1, Ryohei Sasaki2, Daisuke Miyawaki1, Kenji Yoshida1, Hideki Nishimura1, Yasuo Ejima1, Kazuhiro Kitajima3, Miki Saito4, Naoki Otsuki4, Ken-Ichi Nibu4.   

Abstract

OBJECTIVE: This retrospective study analyzed the oncological and treatment outcomes of the patients with T1-T2N0 glottic cancer, who were treated with radiotherapy as initial treatment and salvaged by conservative surgery for radiation failure.
METHODS: Between May 1999 and December 2010, 115 patients with glottic laryngeal cancer were treated at Kobe University Hospital. At presentation, 54 patients had stage T1a disease, 26 had stage T1b disease and 35 had stage T2 disease. Seventy-nine patients were treated with conventional radiotherapy and 36 patients were treated with hyperfractionated radiotherapy as initial treatment.
RESULTS: Median duration of follow-up was 61 months. Five-year local control rates of radiotherapy were 92% in T1a, 83% in T1b and 86% in T2. Of 12 patients who developed local recurrence, larynx was successfully preserved in 3 patients by laryngomicrosurgery, 7 patients by vertical partial laryngectomy and one patient by subtotal laryngectomy. Ultimate 5-year laryngeal preservation rate and local control rate of all cases were 99 and 100%, respectively.
CONCLUSIONS: Present results suggest that initial treatment with radiotherapy salvaged by organ preservation surgery is an effective strategy for laryngeal preservation in the treatment of T1-T2N0 glottic laryngeal cancer.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  glottic cancer; organ preservation; radiotherapy; salvage therapy

Mesh:

Year:  2014        PMID: 25502310     DOI: 10.1093/jjco/hyu203

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  6 in total

1.  Guidelines for the Surgical Management of Laryngeal Cancer: Korean Society of Thyroid-Head and Neck Surgery.

Authors:  Soon-Hyun Ahn; Hyun Jun Hong; Soon Young Kwon; Kee Hwan Kwon; Jong-Lyel Roh; Junsun Ryu; Jun Hee Park; Seung-Kuk Baek; Guk Haeng Lee; Sei Young Lee; Jin Choon Lee; Man Ki Chung; Young Hoon Joo; Yong Bae Ji; Jeong Hun Hah; Minsu Kwon; Young Min Park; Chang Myeon Song; Sung-Chan Shin; Chang Hwan Ryu; Doh Young Lee; Young Chan Lee; Jae Won Chang; Ha Min Jeong; Jae-Keun Cho; Wonjae Cha; Byung Joon Chun; Ik Joon Choi; Hyo Geun Choi; Kang Dae Lee
Journal:  Clin Exp Otorhinolaryngol       Date:  2017-01-03       Impact factor: 3.372

Review 2.  Therapeutic modalities and oncologic outcomes in the treatment of T1b glottic squamous cell carcinoma: a systematic review.

Authors:  Federico Maria Gioacchini; Michele Tulli; Shaniko Kaleci; Stefano Bondi; Mario Bussi; Massimo Re
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-09-19       Impact factor: 2.503

3.  Transoral laser microsurgery for T1b glottic cancer: review of 51 cases.

Authors:  Bernhard G Weiss; Friedrich Ihler; Yiannis Pilavakis; Hendrik A Wolff; Martin Canis; Christian Welz; Wolfgang Steiner
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-27       Impact factor: 2.503

Review 4.  Involvement of the Anterior Commissure in Early Glottic Cancer (Tis-T2): A Review of the Literature.

Authors:  Martine Hendriksma; Elisabeth V Sjögren
Journal:  Cancers (Basel)       Date:  2019-08-23       Impact factor: 6.639

5.  Survival results of 3786 patients with stage I or II laryngeal squamous cell carcinoma: a study based on a propensity score.

Authors:  Genival Barbosa de Carvalho; Hugo Fontan Kohler; Renan Bezerra Lira; José Guilherme Vartanian; Luiz Paulo Kowalski
Journal:  Braz J Otorhinolaryngol       Date:  2020-07-19

6.  Survival and Prognostic Factors for Outcome after Radiotherapy for T2 Glottic Carcinoma.

Authors:  Martine Hendriksma; Marc A P van Ruler; Berit M Verbist; Martin A de Jong; Ton P M Langeveld; Peter Paul G van Benthem; Elisabeth V Sjögren
Journal:  Cancers (Basel)       Date:  2019-09-06       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.